Navigation Links
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Date:8/14/2014

BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND.  The pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin is for use in hemodialysis patients with a central venous catheter.  The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe.  Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

In addition, CorMedix is pleased to announce strategic business collaboration with Wonik Corporation, a South Korean corporation with a strong medical device franchise within the Korean healthcare market.  Wonik has a strong medical franchise and we believe it is well positioned to market, sell and distribute Neutrolin for hemodialysis patients upon receipt of regulatory approval in Korea.

Randy Milby, Chief Executive Officer of CorMedix, stated, "I am very pleased to have signed a definitive agreement with an established commercial partner, Wonik Group in South Korea, a professional and growing healthcare company in one of the key markets in East Asia.  It will of course take some time to gain regulatory approval to market the product."

"In addition, the acceptance of the Neutrolin pivotal Phase 3 clinical trial protocol is a major milestone which provide
'/>"/>

SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
5. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
6. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
7. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
8. Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
9. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
10. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... or the "Company") (NASDAQ: TTHI , TSX: TTH) ... at 5:00 P.M. EST to discuss,the Second Quarter fiscal ... Officer of the Company, will host the call. Transition,will ... press release to,be issued prior to the call. In ...
... Florida biochemist says coral-killing ... synthetics harm humans, too, ORLANDO, Fla., Feb. ... Florida biochemist Celia Ferreira, Ph.D.,advises., Scientists have found a link ... sunscreen that wash off swimmers every,year., According to a study ...
... MedThink Communications, an,innovator in medical communications, brand ... by Salix Pharmaceuticals, Inc, in,Morrisville to launch ... an,orally disintegrating form of metoclopramide., Salix ... orally disintegrating,metoclopramide tablet and will bring the ...
... Statement of Matthew L.,Myers President, Campaign for Tobacco-Free ... will begin negotiations on an historic,international treaty to ... products -- a global problem that funds organized ... and,undermines efforts to reduce tobacco use and save ...
... play a key role in the likelihood their patients ... interventions targeting both the provider and the patient are ... particular must take into account patient barriers such as ... discovered. The study is published in the March 15, ...
... Web pages dedicated to disseminating breast cancer information, researchers ... have determined that while most breast cancer data found ... pages featured inaccuracies and sites displaying complementary and alternative ... or misleading health information. , Published in the ...
Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST 2Health News:Choose Biodegradable Sunscreen to Save Coral Reefs 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 2Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 3Health News:Provider influence and patient barriers affect use of colorectal cancer screening 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2
Bruns bone curette, 9, oval, solid actagonal handle....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
9.5" overall length, 4.5" handle....
Medicine Products: